- Home
- CYTH vs NERV Comparison
CYTH vs NERV Comparison
Compare CYTH & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYTH
- NERV
- Stock Information
- Founded
- CYTH 1990
- NERV 2007
- Country
- CYTH United States
- NERV United States
- Employees
- CYTH N/A
- NERV N/A
- Industry
- CYTH Biotechnology: Pharmaceutical Preparations
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- CYTH Health Care
- NERV Health Care
- Exchange
- CYTH Nasdaq
- NERV Nasdaq
- Market Cap
- CYTH 20.4M
- NERV 18.3M
- IPO Year
- CYTH N/A
- NERV 2014
- Fundamental
- Price
- CYTH $0.69
- NERV $2.19
- Analyst Decision
- CYTH Buy
- NERV Hold
- Analyst Count
- CYTH 3
- NERV 1
- Target Price
- CYTH $0.95
- NERV $5.00
- AVG Volume (30 Days)
- CYTH 21.2K
- NERV 25.4K
- Earning Date
- CYTH 11-14-2024
- NERV 11-05-2024
- Dividend Yield
- CYTH N/A
- NERV N/A
- EPS Growth
- CYTH N/A
- NERV N/A
- EPS
- CYTH N/A
- NERV N/A
- Revenue
- CYTH $870,725.00
- NERV N/A
- Revenue This Year
- CYTH N/A
- NERV N/A
- Revenue Next Year
- CYTH $24.49
- NERV N/A
- P/E Ratio
- CYTH N/A
- NERV N/A
- Revenue Growth
- CYTH N/A
- NERV N/A
- 52 Week Low
- CYTH $0.59
- NERV $2.07
- 52 Week High
- CYTH $2.12
- NERV $13.49
- Technical
- Relative Strength Index (RSI)
- CYTH 47.10
- NERV 41.39
- Support Level
- CYTH $0.61
- NERV $2.08
- Resistance Level
- CYTH $0.77
- NERV $2.35
- Average True Range (ATR)
- CYTH 0.05
- NERV 0.10
- MACD
- CYTH -0.00
- NERV -0.00
- Stochastic Oscillator
- CYTH 55.63
- NERV 40.92
About CYTH Cyclo Therapeutics Inc.
Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.